Gastroenterology
Volume 134, Issue 5 , Pages 1376-1384 , May 2008

Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALT

Received 3 April 2007 ,Accepted 31 January 2008.

References 

  1. Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–774
  2. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056–1075
  3. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the “healthy” hepatitis B carrier state. Hepatology. 1987;7:758–763
  4. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–2094
  5. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut. 2003;53:416–419
  6. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527
  7. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–962
  9. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489
  10. Lok AS. The maze of treatments for hepatitis B. N Engl J Med. 2005;352:2743–2746
  11. Liaw YF, Tsai SL, Ehien RN, et al. Prednisolone priming enhances Th-1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 2000;32:604–609
  12. D'Antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferon-α treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study. J Pediatr. 2006;148:228–233
  13. Sarin SK, Sandhu BS, Sharma BC, et al. Beneficial effects of “lamivudine pulse” therapy in HBeAg-positive patients with normal ALT. J Viral Hepat. 2004;11:552–558
  14. Ricci G, De Bac C, Caramia F. Carriers of hepatitis B antigen: an epidemiologic and histologic study. J Infect Dis. 1973;128:125–128
  15. Tapp E, Jones DM, Hollanders D, et al. Serial liver biopsies in blood donors with persistent HBs antigenaemia. J Clin Pathol. 1976;29:884–886
  16. Dragosics B, Ferenci P, Hitchman E, et al. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–306
  17. de Franchis R, D'Arminio A, Vecchi M, et al. Chronic asymptomatic HBsAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV. Gastroenterology. 1980;79:521–527
  18. Chandra R, Kapoor D, Agarwal SR, et al. High frequency of biochemical and histological disease in incidentally discovered asymptomatic HBsAg positive carrier: need to change terminology. Hepatology. 1999;30(Suppl 2):A1923
  19. Wang C, Deubner H, Shuhart M, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection. (abstr) Hepatology. 2005;42(Suppl 1):A573
  20. Nguyen MH, Trinh H, Garcia RT, et al. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. (abstr 1008) Hepatology. 2005;42(Suppl 1):A593
  21. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311–321
  22. Brunetto MR, Giarin M, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991;88:4186–4190
  23. Berger A, Braner J, Doerr HW, et al. Quantification of viral load: clinical relevance for human immunodeficiency virus, hepatitis B and hepatitis C virus infection. Intervirology. 1998;41:24–34
  24. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology. 2001;120:1828–1853
  25. Chu CJ, Lok AS. Clinical utility in quantifying serum HBV DNA levels using PCR assays. J Hepatol. 2002;36:549–551
  26. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002;36:543–546
  27. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408–1415
  28. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV DNA levels in inactive hepatitis B virus carriers. Gastroenterology. 2002;122:2092–2093
  29. Seo Y, Yoon S, Truong BX, et al. Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2005;17:753–757
  30. Indian Association for Study of the Liver (INASL). Changing terminology of hepatitis B and C carrier: consensus statement. Ind J Gastroenterology. 1999;18(Suppl 1):S21–S28
  31. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–9
  32. Wakil SM, Kazim SN, Khan LA, et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol. 2002;68:311–318
  33. Kazim SN, Sarin SK, Sharma BC, et al. Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India. Intervirology. 2006;49:152–160
  34. Kirschberg O, Schuttler C, Repp R, et al. A multiplex-PCR to identify hepatitis B virus genotypes A-F. J Clin Virol. 2004;29:39–43
  35. Lindh M, Horal P, Dhillon AP, et al. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen stage show more severe liver damage. Hepatology. 1996;24:494–501
  36. Chauhan R, Kazim SN, Bhattacharjee J, et al. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol. 2006;78:1047–1054
  37. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435
  38. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16
  39. Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393–1398
  40. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy patients: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C (MULTIVIRC Group). Hepatology. 1998;27:1213–1219
  41. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983–988
  42. Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091–2097
  43. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  44. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758
  45. Iloeje UH, Yang HI, Su J, et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
  46. Sarin SK, Kumar M, Tyagi P. HBV carrier or chronic HBV infection: need for change in terminology. J Gastroenterol Hepatol. 2004;19(Suppl):S103–S107

 Conflicts of interest: There are no conflicts of interest to disclose.

PII: S0016-5085(08)00356-9

doi: 10.1053/j.gastro.2008.02.075

Gastroenterology
Volume 134, Issue 5 , Pages 1376-1384 , May 2008

Article Tools

* Image Usage & Resolution